PROTECTION AND FLEXIBILITY ON THE GO[a]

Esperoct has a flexibility factor that offers the broadest temperature stability[a] and compact packaging for all ages

Bradley has severe hemophilia A and uses Esperoct®.

EHL=extended half-life.

[a]Esperoct® can be stored at room temperature up to 86 °F for up to 12 months **or** up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

WHAT IS ESPEROCT®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

- Esperoct® is not used to treat von Willebrand Disease

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

novo nordisk®

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

Esperoct® has the **highest storage temperature** of **ALL EHL** products



Esperoct® offers **portable** and **flexible storage** across **ALL AGE GROUPS**

IMPORTANT SAFETY INFORMATION

Who should not use Esperoct®?

- You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

A flexibility factor that can fit into your schedule

After reconstitution, Esperoct® can be:

Used up to
4 HOURS

at up to
86 °F

OR

Stored in the refrigerator between
36 °F TO 46 °F

for up to
24 HOURS

See Prescribing Information for complete product storage information. Store reconstituted product in vial.

Bradley has severe hemophilia A and uses Esperoct®.

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

novo nordisk®

Ready in **3 simple steps**

1 Attach

Prefilled diluent syringe contains 4 mL of diluent—works with any dose strength

2 Twist

Adapter connects the syringe and vial with a 25 µm inline particle filter

3 Mix

After mixing, the reconstituted solution can be administered

A prefilled syringe provides convenient administration over 2 minutes

5 vial sizes
for personalized treatment

Please note, these are not the complete Esperoct® Instructions for Use. Please see the Instructions for Use provided with the Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I need to know about Esperoct®?

- **Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center**

Esperoct® can **go with you**

Carry your factor and supplies in a portable, reusable kit

Designed to fit into your life

Compact packaging
for easy storage

Take it with you
Esperoct® Small Kit

See Prescribing Information for complete product storage, reconstitution, and administration information.

Esperoct® has a flexibility factor that fits into your active lifestyle

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

Esperoct® prophylaxis with **simple dosing**

Switch to fewer infusions than SHLs with a standard **50 IU/kg dose every 4 days**.

No dose adjustment needed. Esperoct® dosing frequency can be individualized to meet your needs

50% **FEWER INFUSIONS** if you previously infused **every other day**

Fewer infusions per year compared with SHL dosing regimens

40% **FEWER INFUSIONS** if you previously infused **3x/week**

Esperoct® delivers high factor levels from one dose to the next

Factor levels stay **at or above 3%** for

Factor activity between 1% to 5% is defined as moderate hemophilia

Factor levels stay **at or above 5%** for

Factor activity 5% and above is defined as mild hemophilia

Long-term prophylaxis of

Maintained about 5% trough levels[d] (n=53)

[a]Trough level goal is 1% for prophylaxis. Trough level is when your factor is at the lowest before your next infusion.
[b]Data shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits.
[c]Steady-state Factor 8 activity levels were estimated in 143 adults and adolescents using pharmacokinetic (PK) modeling.
[d]An analysis was performed on data from a trial of patients 12 years and older with severe hemophilia A. Mean Factor 8 trough levels were measured over time in 53 patients who received Esperoct® 50 IU/kg every 4 days for 6 years or more. Several trough levels were not included in the analysis if they were taken soon after extra dosing to treat a bleed.

novo nordisk®

Esperoct® extends half-life **beyond the standard**

22-hour average half-life in adults[e]

Half-life is the time it takes for the level of factor in your blood to fall by 50% (half) after an infusion.



Esperoct® is made by taking the existing Novoeight® (rFVIII) molecule and adding PEGylation technology to extend the half-life.

Novoeight® Antihemophilic Factor (Recombinant)

rFVIII=recombinant Factor 8.
SHL=standard half-life.

[e]Data shown are from 42 adults who received a PK assessment around the first Esperoct® 50 IU/kg dose.
[f]Data shown are from a comparison study of 26 previously treated patients (PTPs) 18 years or older who received a 25, 50, or 75 IU/kg dose of their previous SHL product followed by the same dose of Esperoct®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I need to know about Esperoct®? (cont'd)

- **Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as:** hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

Esperoct® Prophylaxis

Stay protected from bleeds

Dose less often[a] without sacrificing protection

Bradley has hemophilia A and uses Esperoct®.

1.2	0.9	0	0
Overall bleeds per year[b]	Joint bleeds per year[b]	Spontaneous bleeds per year[b]	Traumatic bleeds per year[b]

Long-term trial results–up to 6.6 years[c]

0.8	0
Overall bleeds per year[c] (N=177)	**Annual bleeds after the first year** in majority of adults and adolescents who completed the entire trial[d]

[a]Compared to SHL products, 50% fewer infusions when administered every other day and 40% fewer when administered 3x weekly.
[b]Data shown are from the main phase of a study of 175 previously treated people aged 12 and older with severe hemophilia A who received Esperoct® 50 IU/kg every 4 days for 76 weeks. Median annualized bleeding rates are shown.
[c]Median annualized bleeding rate shown is from the main and extension phases of the pivotal clinical trial of previously treated people aged 12 and older with severe hemophilia A who received Esperoct® 50 IU/kg every 4 days, for up to 6.6 years.
[d]Based on a post hoc analysis of patients who completed the entire trial (n=110) who took Esperoct® 50 IU/kg every 4 days for up to 6.6 years. Patients evaluated at Year 2 (n=103), Year 3 (n=66), Year 4 (n=62), and Year 5 (n=62), Year 6 (n=59).

Esperoct® On-Demand

Bleed control you can count on

Control for the treatment of bleeding episodes

97%

of bleeds controlled with **1 to 2 infusions**[e]

Dosing for the treatment of bleeding episodes in adults and adolescents

40 IU/kg for minor-to-moderate bleeds

50 IU/kg for major bleeds

For moderate-to-major bleeds, additional dose(s) may be administered every 24 hours.

Tammy has hemophilia A and uses Esperoct®.

[e]Data shown are from a study where 12 adult and adolescent PTPs with severe hemophilia chose to be treated on demand and received Esperoct® for 532 bleeding episodes.

IMPORTANT SAFETY INFORMATION (cont'd)

What should I tell my healthcare provider before using Esperoct®?

- Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

Protection that keeps up with children

Esperoct® achieved a

14.3 HOUR average **half-life** in children[a]

85% LONGER **half-life** compared to SHL[b]

Factor levels stay **at or above 2%** for children aged 6 to 11

100% of the time[c,d]

Factor activity between 1% to 5% is defined as moderate hemophilia

Long-term prophylaxis of

More than **5 years**

Maintained about 4% trough levels[e] (n=54)

[a]Comparison to prior Factor 8 product was performed at the beginning of the study in previously treated children. The geometric mean terminal half-life in 22 children aged 0 to 11 was 14.3 hours. Esperoct® geometric mean terminal half-life was 14.7 hours in 12 children aged 0 to 5 years old and 13.8 hours in 10 children aged 6 to 11 years old.

[b]Comparison to prior Factor 8 product was performed at the beginning of the study in previously treated children. Esperoct® half-life was 14.7 hours in 12 children aged 0 to 6 years old and 13.8 hours in 10 children aged 6 to 11 years old.

[c]Trough level goal is 1% for prophylaxis. Trough level is when your factor is at the lowest before your next infusion.

[d]Data shown are from a study where 34 previously treated children received routine prophylaxis with Esperoct® 60 IU/kg (50 to 75 IU/kg) twice weekly. Pre-dose factor activity (trough) levels were evaluated at follow-up visits.

[e]Post hoc analyses were performed on data from a trial of patients aged 11 and under with severe hemophilia A. Mean Factor 8 trough levels were measured over time in 54 patients who received twice-weekly prophylaxis for 5 years or more. Limitations of the analyses include the exclusion of several trough-level data if believed that they were elevated due to dosing to treat a recent bleed.

IMPORTANT SAFETY INFORMATION (cont'd)

What should I tell my healthcare provider before using Esperoct®? (cont'd)

- Your body can make antibodies called "inhibitors" against Esperoct®, which may stop Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®**

Simple dosing with a **flexibility factor** allows for **fewer infusions** than SHLs

One standard dose makes it easy to switch

65 IU/kg twice weekly

No dose adjustment needed.[f]

Because Factor 8 products may be cleared from the body faster in children under 12, higher and more frequent dosing may be needed.

43% FEWER INFUSIONS if your child previously **infused every other day**

Fewer infusions per year compared with SHL dosing regimens

33% FEWER INFUSIONS if your child previously **infused 3x/week**

Model for illustrative purposes only.

[f]This regimen may be individually adjusted to less or more frequent dosing based on bleeding episodes.

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

Reduce bleeding episodes

Low number of bleeds per year for children under 12[a]

Model for illustrative purposes only.

2.0
Overall bleeds per year[a]

0
Joint bleeds per year[a]

0
Spontaneous bleeds per year[a]

0
Traumatic bleeds per year[a]

[a]Data shown are from a study of 68 previously treated children (34 aged 0 to 5 years old and 34 aged 6 to 11 years old) who received an average dose of approximately 65 IU/kg twice weekly for 26 weeks. Median annualized bleeding rates are shown.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of Esperoct®?

- Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Long-term trial results–up to 5.4 years[b]

Percentage of children who experienced

0.8
Overall Bleeds
per year[b]
(N=68)

0
Annual Bleeds
more than doubled from Year 1 to Year 5[c]

100% resolution
of target joints[d]

[b]Median annualized bleeding rate shown is from the main and extension phases of the clinical trial in previously treated children with severe hemophilia A, for a median of 5 years.
[c]Based on a post hoc analysis of patients who completed the entire trial who took Esperoct® 60 IU/kg (50 IU/kg to 75 IU/kg) twice weekly for up to 5 years (n=63). Approximately 32% of the patients that participated in both the main and extension phases experienced no bleeding episodes during Year 1, about 50% during Year 2, less than 50% during Year 3, 56% during Year 4, and about 70% during Year 5 had no annual bleeding episodes.
[d]A target joint was defined as a single joint with 3 or more bleeding episodes in 6 consecutive months. All baseline target joints reached definition of target joint resolution (if there were no bleeding episodes for 12 consecutive months) in slightly over 2 years of treatment with Esperoct®. Twelve patients with 16 documented target joints at baseline participated in the main and extension phases of the clinical trial.

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

Esperoct® was studied in one of the **largest and longest clinical trial programs**

Safety proven across 5 clinical studies

- 0 blood clots
- No PEG-related safety concerns
- One PTP with a high-risk gene mutation developed an inhibitor to Factor 8[a]
  - The development of inhibitor is similar to the reported rate in patients with severe hemophilia A (0.15 per 100 patient years)[b]

[a]An 18-year-old African American male developed an inhibitor after 93 infusion days of Esperoct®. The inhibitor rose to 13.5 Bethesda units and the patient stopped participation in the study. There was no change in efficacy, and the inhibitor eventually went away on its own (without use of immune tolerance induction therapy).
[b]Patient year is the patient experience under treatment of 1 year's duration. For example, 1 patient year is equal to the experience of 2 patients for 6 months, or 12 patients for 1 month each.

IMPORTANT SAFETY INFORMATION (cont'd)

What should I tell my healthcare provider before using Esperoct®? (cont'd)

- Your body can make antibodies called "inhibitors" against Esperoct®, which may stop Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®**

Patient support with NovoCare® (NovoSecure™)

You may be eligible for:

Free Trial Product Program
Talk to a NovoCare® specialist to find out if you're eligible[a]

Product Assistance Program
Apply for the Product Assistance Program by calling 1-844-NOVOSEC (1-844-668-6732) for more information[b]

Co-pay Assistance Program
Get help with co-pay costs for Esperoct®, up to $12,000[c]

Speak with a NovoCare® specialist
Visit Novocare.com or call 1-844-NOVOSEC (1-844-668-6732)

[a]Patients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
[b]The Novo Nordisk Patient Assistance Program (PAP) is administered by NovoCare®. To qualify for the PAP, patients must demonstrate financial need and must have attempted to find alternative reimbursement. Several factors are considered in evaluating financial need, including cost of living, size of household, and burden of total medical expenses. If the applicant qualifies under the PAP guidelines, a limited supply of the requested medication(s) will be shipped to the patient. Patients who qualify for PAP may be eligible to receive the prescribed Novo Nordisk product, for up to 1 year from the approval date. Product limits vary.
[c]Novo Nordisk Hemophilia and Rare Bleeding Disorders Copay/Coinsurance Terms and Conditions: Enrolled patients are eligible for up to $12,000 in co-pay/coinsurance assistance per calendar year for each NNI hemophilia or rare bleeding disorder product. Assistance is retroactive to 60 days. Patients must be commercially insured and may not be participating in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance. Uninsured, cash-paying patients are not eligible to participate. Patients are eligible to receive co-pay/coinsurance assistance on an annual basis (12 months). Offer good only in the USA, Puerto Rico, Guam, Saipan, and Virgin Islands with participating pharmacies and cannot be redeemed at government-subsidized clinics. Void where taxed, restricted, or prohibited by law. Absent of a change in Massachusetts law, effective July 1, 2019, the Savings Card will no longer be valid for residents of Massachusetts. Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. This is not an insurance program. Novo Nordisk reserves the right to rescind, revoke, or amend this offer without notice at any time. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible. Must have a current prescription for an FDA-approved indication.

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei

PROTECTION AND FLEXIBILITY ON THE GO[a]

ESPEROCT® has a flexibility factor that offers the broadest temperature stability[a] and compact packaging for all ages

A flexibility factor that can fit into your schedule

- After reconstitution, Esperoct® can be
  - Used up to 4 hours when stored at up to 86 ˚F **OR**
  - Stored in the refrigerator at up to 36 ˚F to 46 ˚F for up to 24 hours

Switch to fewer infusions than SHLs with a standard 50 IU/kg dose every 4 days

- 50% fewer infusions for adults and adolescents who previously infused every other day
- 43% fewer infusions if your child previously infused every other day

Portability with compact packaging and easy storage[a]

For prophylactic and on-demand use across all ages



[a]Esperoct® can be stored at room temperature up to 86 °F for up to 12 months **or** up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

IMPORTANT SAFETY INFORMATION (cont'd)

Who should not use Esperoct®?

- You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark of Novo Nordisk A/S
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2023 Novo Nordisk All rights reserved. US22ESP00069 January 2023

esperoct®
antihemophilic factor (recombinant), glycopegylated-exei